The U.S. Food and Drug Administration approved an oral treatment from Roche Holding AG and PTC Therapeutics Inc. for spinal muscular atrophy in adults and children two months and above.
Shares of Biogen jumped more than 11 percent after the company announced the U.S. Food and Drug Administration accepted the Biologics License Application (BLA) for aducanumab, an investigational treatment for Alzheimer’s disease.
Moderna Inc. said smaller volume agreements for the company’s experimental coronavirus vaccine have been priced in the range of $32 to $37 per dose, higher than the price set by the U.S. deal for Pfizer Inc.’s vaccine candidate.
Novavax Inc.’s experimental Covid-19 vaccine produced high levels of antibodies against the novel coronavirus, according to initial data from a small, early-stage clinical trial, sending the company’s shares up 10%.
Shares of CymaBay Therapeutics soared after the company announced the experimental primary biliary cholangitis (PBC) treatment seladelpar hit the mark in a Phase III study that sets up potential regulatory approval for this indication.
U.S. drugmaker Eli Lilly & Co. is beginning a late-stage trial to study whether one of the company’s experimental Covid-19 antibody treatments can prevent the spread of the virus in residents and staff at U.S. nursing homes.
Johnson & Johnson kicked off U.S. human safety trials for a Covid-19 vaccine after releasing details of a study in monkeys that showed the company’s best-performing vaccine candidate offered strong protection in a single dose.
British drugmaker AstraZeneca topped second-quarter sales and profit estimates and backed the company’s 2020 forecasts, helped by strong sales in lockdowns of a diverse product range that includes a potential coronavirus vaccine.
Roche’s attempt to retool the company’s rheumatoid arthritis drug Actemra/RoActemra to treat patients hospitalized with severe Covid-19-related pneumonia failed in a late-stage trial.
Moderna Inc. and Pfizer Inc. launched two 30,000-subject trials of Covid-19 vaccines that could clear the way for regulatory approval and widespread use by the end of 2020.
